The BenevolentAI platform enables novel discoveries throughout the drug discovery process
End-to- end Drug discovery offerings
Clinical sub-typing
Mechanism recommandation
Target prediction and assessment
Experimental hypothesis validation
In-silico led HitID
In-silico led LeadOp
Biomarker assessment
Indication expansion and drug repurposing
PARTNERING
We partner with leading pharmaceutical and biotech companies to help them unlock biological insights and tackle complex therapeutic challenges.